2-((1H-indol-4-yl)oxy)ethanamine | 246028-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-((1H-indol-4-yl)oxy)ethanamine
• 英文别名: 2-(1H-indol-4-yloxy)ethylamine；2-(1H-indol-4-yloxy)ethanamine
• CAS: 246028-97-7
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: FZXIBIRCACCXGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((1H-indol-4-yl)oxy)ethanamine 在 三乙烯二胺 、 ferrous(II) sulfate heptahydrate 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 1.25h， 生成 (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(indolin-4-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone
  参考文献：
  名称：

  发现新型pERK1 / 2或β-arrestin偏爱的5-HT1A受体偏向激动剂：多种治疗样与副作用的关系。

  摘要：

  获得了对5-羟色胺5-HT 1A受体具有高亲和力和选择性的新型1-（1-苯甲酰基哌啶丁-4-基）甲胺衍生物，并在四种功能测定中进行了测试：ERK1 / 2磷酸化，腺苷酸环化酶抑制，钙动员和β-抑制蛋白的募集。选择化合物44和56（分别为2-甲基氨基苯氧基乙基和2-（1 H-吲哚-4-基氧基）乙基衍生物）作为具有高度差异性的“信号指纹”的偏向激动剂，这些信号被翻译成不同的体内特征。在体外，44显示出对ERK1 / 2磷酸化的偏向激动作用，而在体内，它在大鼠Porsolt强迫游泳试验中优先发挥了抗抑郁样作用。相反，化合物56表现出一流的特性：它在体外优先有效地激活β-arrestin募集，并在体内有效引起下唇缩回，这是“ 5-羟色胺能综合症”的一个组成部分。两种化合物均显示出良好的可显影性。提出的5-HT 1A受体偏向激动剂，优先针对各种信号传导途径，有可能成为独特的中枢神经系统病理学的候选药

  DOI：

  10.1021/acs.jmedchem.0c00814
• 作为产物：
  描述：

  4-羟基吲哚 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 甲胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 51.0h， 生成 2-((1H-indol-4-yl)oxy)ethanamine
  参考文献：
  名称：

  发现新型pERK1 / 2或β-arrestin偏爱的5-HT1A受体偏向激动剂：多种治疗样与副作用的关系。

  摘要：

  获得了对5-羟色胺5-HT 1A受体具有高亲和力和选择性的新型1-（1-苯甲酰基哌啶丁-4-基）甲胺衍生物，并在四种功能测定中进行了测试：ERK1 / 2磷酸化，腺苷酸环化酶抑制，钙动员和β-抑制蛋白的募集。选择化合物44和56（分别为2-甲基氨基苯氧基乙基和2-（1 H-吲哚-4-基氧基）乙基衍生物）作为具有高度差异性的“信号指纹”的偏向激动剂，这些信号被翻译成不同的体内特征。在体外，44显示出对ERK1 / 2磷酸化的偏向激动作用，而在体内，它在大鼠Porsolt强迫游泳试验中优先发挥了抗抑郁样作用。相反，化合物56表现出一流的特性：它在体外优先有效地激活β-arrestin募集，并在体内有效引起下唇缩回，这是“ 5-羟色胺能综合症”的一个组成部分。两种化合物均显示出良好的可显影性。提出的5-HT 1A受体偏向激动剂，优先针对各种信号传导途径，有可能成为独特的中枢神经系统病理学的候选药

  DOI：

  10.1021/acs.jmedchem.0c00814

文献信息

• Studies towards the next generation of antidepressants. Part 4: Derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor
  作者：Deborah A. Evrard、Ping Zhou、Soo Y. Yi、Dahui Zhou、Deborah L. Smith、Kelly M. Sullivan、Geoffrey A. Hornby、Lee E. Schechter、Terrance H. Andree、Richard E. Mewshaw

  DOI：10.1016/j.bmcl.2004.12.064

  日期：2005.2

  Derivatives of the serotonin reuptake inhibitor 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine, in which serotonin 1A (5-HT(1A)) receptor pharmacophoric elements are incorporated, are reported. Analogs exhibiting affinity for both the serotonin transporter and the 5-HT(1A) receptor are described. Compounds containing 1-(4-indolyl)piperazine and 2-(1H-indol-4-yloxy)ethylamine are promising leads for further

  据报道了5-羟色胺再摄取抑制剂4-（5-氟-1H-吲哚-3-基）环己胺的衍生物，其中并入了5-羟色胺1A（5-HT（1A））受体药效学元素。描述了对血清素转运蛋白和5-HT（1A）受体都表现出亲和力的类似物。含有1-（4-吲哚基）哌嗪和2-（1H-吲哚-4-基氧基）乙胺的化合物是进一步SAR研究的有前途的线索。
• SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES
  申请人：ADAMED SP. Z O.O

  公开号：US20150051257A1

  公开（公告）日：2015-02-19

  Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O) x —(CH2) y — through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C 1 -C 3 -alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring; and bicyclic group consisting of benzene ring fused with—or 6-membered non-aromatic heterocyclic ring having 1 or 2 heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon N atoms of benzene ring; R represents H or —CH 3; x is 0 or 1; y is 2 or 3; and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents —CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

  苯甲胺的磺胺基衍生物，其化学式（I）中，A代表未取代或取代的苯基；或与—(O)x—(CH2)y—连接的9-或10-成员双环族，通过其芳香碳原子之一，由与含1或2个异原子（N和O）中独立选择的群组成的芳香环并联的苯环构成，其中此类双环族未取代或取代，或者与含1或2个O原子的5-或6-成员非芳香杂环取代或未取代，其中杂环未取代或取代为一个或多个C1-C3-烷基；D代表选自：未取代或取代的苯基；未取代或取代的萘基；未取代或取代的噻吩基；由咪唑环并联的5-成员非芳香碳环组成的双环族；由苯环并联的含1或2个异原子（N、O和S）中独立选择的群组成的5-成员杂芳环，未取代或取代，并通过苯环的一个碳原子之一与磺胺基团连接；以及由苯环并联的含1或2个异原子（N和O）中独立选择的群组成的5-或6-成员非芳香杂环取代或未取代，并通过苯环的一个碳N原子之一与磺胺基团连接；R代表H或—CH3；x为0或1；y为2或3；以及其药学上可接受的盐和溶剂合物，但如果x为0且y为2，则D为未取代或取代的萘基，且如果R代表—CH3，则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
• [EN] SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES<br/>[FR] DÉRIVÉS DE SULFONAMIDE DE LA BENZYLAMINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL (SNC)
  申请人：ADAMED SP ZOO

  公开号：WO2013140347A1

  公开（公告）日：2013-09-26

  Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted;or 9-or 10-membered bicyclic group, linked to –(O) x - (CH 2 ) y -through one of its aromatic carbon atoms,consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5-or 6-membered non-aromaticheterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1 -C3 - alkyls; D represents a group selected from:phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted;thiophene unsubstituted or substituted;bicyclic group consisting of imidazolering fused with5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring;and bicyclic group consisting of benzene ring fused with -or 6-membered non-aromatic heterocyclic ring having 1 or 2heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon atoms of benzene ring;R represents H or –CH 3;x is 0 or 1;yis 2 or 3;and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents –CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

  苯甲胺的磺胺基衍生物的化学式（I），其中A代表未取代或取代的苯基；或9-或10-成员的双环族，通过其中一个芳香碳原子连接到-(O) x - (CH 2 ) y -，由苯环与含有1个或2个杂原子（从N和O组成的组中独立选择）的-成员杂芳环融合而成，其中该双环族未取代或取代，或与含有1个或2个O原子的5-或6-成员非芳杂环取代，其中杂环未取代或取代为一个或多个C1 -C3 -烷基；D代表从中选择的一组：未取代或取代的苯基；未取代或取代的萘基；未取代或取代的噻吩基；由咪唑环融合而成的5-成员非芳碳环的双环族；由苯环融合而成的含有1个或2个杂原子（从N、O和S组成的组中独立选择）的5-成员杂芳环的双环族，未取代或取代，并通过苯环的一个碳原子与磺胺基团连接；以及由苯环融合而成的5-或6-成员非芳杂环的双环族，其中杂原子独立选择自N和O组成的组，未取代或取代，并通过苯环的一个碳原子与磺胺基团连接；R代表H或-CH 3；x为0或1；y为2或3；以及其药学上可接受的盐和溶剂化合物，但是如果x为0且y为2，则D为未取代或取代的萘基且带有一个卤原子，如果R代表-CH 3，则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
• Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
  申请人：——

  公开号：US20040019044A1

  公开（公告）日：2004-01-29

  The invention relates to heterocyclic aminoalkylpyridine derivatives of the formula I 1 where R 1 is the radical of a heterocycle having 1 to 3 ring structures, where each ring structure is saturated, unsaturated or aromatic and optionally fused to other ring structures to give a fused ring system and the heterocycle has a total of 1 to 4 N, O and/or S atoms in the ring structures and is optionally monosubstituted, disubstituted or trisubstituted by one or more of the groups —A, —OR 4 , —N(R 4 ) 2 , —NO 2 , —CN, Hal, —COOR 4 , —CON(R 4 ) 2 , —COR 4 , ═O; R 2 is a phenyl group which is optionally monosubstituted, disubstituted, trisubstituted, tetrasubstituted or pentasubstituted by one or more of the groups Hal, —A, —O—A, —NO 2 or —CN, or is a thienyl group which is optionally monosubstituted or disubstituted by one or more of the groups Hal, —A, —O—A, —NO 2 , —CN or thienyl; R 3 is H, —A, —CO—A, —C(R 4 ) 2 R 2 , —C(R 4 ) 2 -pyridinediyl-R 2 ; R 4 is H or —A; A is C 1 -C 6 -alkyl, where 1 to 7 hydrogen atoms are optionally replaced by fluorine; —X— is —O—, —S—, sulfinyl, sulfonyl, —C(R 4 ) 2 —; —Y— is —[C(R 4 ) 2 ] n —; —Z— is —C(R 4 ) 2 —; Hal is F, Cl, Br or I; n is 1, 2, 3 or 4; and their tolerable salts and solvates and their use as medicaments.

  该发明涉及公式I1的杂环氨基烷基吡啶衍生物，其中R1是具有1到3个环结构的杂环的基团，每个环结构是饱和的、不饱和的或芳香的，并且可选择地与其他环结构融合以形成融合环系统，杂环在环结构中总共有1到4个N、O和/或S原子，并且可选择地通过一个或多个基团—A、—OR4、—N(R4)2、—NO2、—CN、Hal、—COOR4、—CON(R4)2、—COR4、═O进行单取代、双取代或三取代；R2是苯基，该苯基可选择地通过一个或多个基团Hal、—A、—O—A、—NO2或—CN进行单取代、双取代、三取代、四取代或五取代，或者是噻吩基，该噻吩基可选择地通过一个或多个基团Hal、—A、—O—A、—NO2、—CN或噻吩进行单取代或双取代；R3是H、—A、—CO—A、—C(R4)2R2、—C(R4)2-吡啶基-R2；R4是H或—A；A是C1-C6-烷基，其中1到7个氢原子可选择地被氟取代；—X—是—O—、—S—、砜基、磺酰基、—C(R4)2—；—Y—是—[C(R4)2]n—；—Z—是—C(R4)2—；Hal是F、Cl、Br或I；n是1、2、3或4；以及它们的可耐受盐和溶剂化合物及其作为药物的用途。
• N-aryloxyethylamine derivatives for the treatment of depression
  申请人：American Home Products Corp.

  公开号：US06110956A1

  公开（公告）日：2000-08-29

  Compounds effective in treating disorders of the serotonin-affected neurological systems are provided, such compounds having the following formula: ##STR1## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring; R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl; R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy; R.sub.5 is hydrogen, lower alkyl, or halogen; R.sub.6 is hydrogen, lower alkyl, or phenyl; R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; and X is (CH.sub.2).sub.n, wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.

  提供了用于治疗受血清素影响的神经系统疾病的化合物，该化合物具有以下结构式：##STR1## 其中：R.sub.1和R.sub.2各自独立地是氢、卤素、CF.sub.3、较低的烷基、较低的烷氧基、MeSO.sub.2，或者一起形成5-7个成员的碳环或杂环；R.sub.3是烷氧基、卤素、氢或者氨基甲酰基；R.sub.4是氢、羟基、较低的烷基或较低的烷氧基；R.sub.5是氢、较低的烷基或卤素；R.sub.6是氢、较低的烷基或苯基；R.sub.7是氢、较低的烷基、较低的烷氧基、卤素、CN、CF.sub.3或羟基；X是(CH.sub.2).sub.n，其中n为0至3；或其药学上可接受的盐。